drugset / Trial / NCT01878292

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

NCT01878292

Phase 3 Completed 529 enrolled Forest Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.

Timeline

Start
2013-07-11
Primary completion
2016-03-17
Completion
2016-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilazodone Small molecule 15 mg Oral
Subject Vilazodone Small molecule 30 mg Oral